"We currently have an approximate $8.4 million cash balance in the bank..."

"Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company's common stock over the 36-month term of the Purchase Agreement. As of June 30, 2015, the available proceeds from Aspire is $29.7 million. "

"We expect to incur costs of approximately $17.7 million in the upcoming twelve (12) months to operate our business"

http://www.sec.gov/Archives/edgar/data/135525...ix_10k.htm

$38.1 million available to do $17.1 million of work in the next year, which includes:
- Brilacidin Phase III (leading to a lucrative partnership)
- Kevetrin Phase I completion (possibly leading to a lucrative partnership)
- Purisol Phase II completion (possibly leading to a lucrative partnership)
- Brilacidin-OM Phase II completion (possibly leading to a lucrative partnership)
- beginning of Kevetrin Phase II AML - paid for by University of Bologna(possibly leading to a lucrative partnership)
- beginning of Kevetrin Phase II Ovarian alone and in combination (possibly leading to a lucrative partnership)
- beginning of Kevetrin Phase I for pediatric retinoblastoma
- completion of gram-negative preclinical studies on HPD mimetics
- more